EURneffy: Uses, Dosage & Side Effects

What Is EURneffy and What Is It Used For?

EURneffy contains epinephrine (also known as adrenaline), a naturally occurring hormone and neurotransmitter produced by the adrenal glands. Epinephrine has been the cornerstone of anaphylaxis treatment for over a century and is recognized by the World Health Organization (WHO), the European Academy of Allergy and Clinical Immunology (EAACI), and the World Allergy Organization (WAO) as the first-line treatment for anaphylaxis. What makes EURneffy unique is its delivery method: rather than requiring a needle injection into the thigh muscle (as with traditional auto-injectors like EpiPen or Jext), EURneffy is sprayed directly into the nostril, offering a completely needle-free approach to epinephrine delivery.

Anaphylaxis is a severe, potentially life-threatening systemic allergic reaction that typically develops rapidly, often within minutes of exposure to a triggering allergen. Common triggers include food allergens (such as peanuts, tree nuts, milk, eggs, shellfish, and wheat), insect venom (from bee stings, wasp stings, or fire ant bites), medications (including antibiotics, nonsteroidal anti-inflammatory drugs, and contrast media), latex, and exercise. In some cases, the trigger remains unidentified, a condition known as idiopathic anaphylaxis. The pathophysiology of anaphylaxis involves a massive release of inflammatory mediators (including histamine, tryptase, leukotrienes, and prostaglandins) from mast cells and basophils, triggered by cross-linking of allergen-specific immunoglobulin E (IgE) antibodies on cell surfaces. This cascade leads to widespread vasodilation, increased vascular permeability, bronchospasm, and mucous membrane edema, which together can cause cardiovascular collapse, airway obstruction, and death if untreated.

Epinephrine counteracts these pathological processes through its action on multiple adrenergic receptor subtypes. Stimulation of alpha-1 adrenergic receptors causes vasoconstriction, which raises blood pressure and reduces mucosal edema, including swelling in the airway. Beta-1 receptor activation increases the rate and force of cardiac contraction, helping to restore cardiac output and blood pressure. Beta-2 receptor stimulation causes bronchodilation (opening of the airways) and inhibits further release of inflammatory mediators from mast cells and basophils. These combined effects make epinephrine uniquely suited as a first-line emergency treatment for anaphylaxis, addressing the cardiovascular, respiratory, and immunological components of the reaction simultaneously.

The intranasal delivery route of EURneffy exploits the rich vascular network of the nasal mucosa, which allows for rapid absorption of epinephrine into the systemic circulation. The nasal cavity has a large surface area, thin epithelium, and abundant blood supply, making it an excellent route for drug absorption. Clinical pharmacokinetic studies have demonstrated that EURneffy achieves systemic epinephrine concentrations comparable to those achieved with standard intramuscular injection of 0.3 mg epinephrine auto-injectors, despite using a higher dose (2 mg) to compensate for the different absorption characteristics of the nasal route. The higher nasal dose accounts for the fact that a proportion of the drug may not be fully absorbed through the nasal mucosa, ensuring that adequate systemic levels are reached to treat the anaphylactic reaction effectively.

The development of a needle-free epinephrine delivery system addresses several well-documented barriers to the effective use of epinephrine auto-injectors. Research has consistently shown that many patients and caregivers hesitate or fail to use auto-injectors during anaphylactic emergencies due to needle phobia, confusion about proper injection technique, fear of causing harm, and the psychological stress of the emergency situation. Studies have found that up to 83% of patients at risk of anaphylaxis do not carry their auto-injectors consistently, and many who do carry them fail to administer them during a reaction. By eliminating the needle, EURneffy removes one of the most significant psychological barriers to epinephrine use, potentially improving the rate and speed of epinephrine administration during anaphylactic emergencies.

What Should You Know Before Taking EURneffy?

Epinephrine is the only first-line treatment for anaphylaxis, and there are no absolute contraindications to its use in a life-threatening allergic reaction. This is a critical point emphasized by all major allergy and emergency medicine guidelines worldwide. Even in patients with known cardiovascular disease, elderly patients, or those taking medications that might interact with epinephrine, the benefit of treating anaphylaxis far outweighs the potential risks of epinephrine administration. Delaying or withholding epinephrine during anaphylaxis is associated with a significantly higher risk of death or severe complications.

Contraindications

There are no absolute contraindications to the use of epinephrine for the emergency treatment of anaphylaxis. However, in non-emergency situations, epinephrine should be used with caution in patients with known hypersensitivity to any of the excipients in the formulation. It is important to understand that the presence of any medical condition does not preclude the use of epinephrine during anaphylaxis. The European Medicines Agency (EMA), the U.S. Food and Drug Administration (FDA), and all international allergy guidelines agree that epinephrine should be administered promptly in any suspected anaphylactic reaction, regardless of the patient's comorbidities.

Warnings and Precautions

While epinephrine is the essential treatment for anaphylaxis, certain patient groups may experience more pronounced cardiovascular effects and should be monitored more closely after administration. These include patients with coronary artery disease, cardiac arrhythmias, hypertension, hyperthyroidism, pheochromocytoma, and diabetes mellitus. Epinephrine can increase heart rate, blood pressure, and myocardial oxygen demand, which may be of particular concern in patients with pre-existing cardiac conditions. However, international guidelines clearly state that anaphylaxis itself poses a far greater immediate risk to these patients than the potential cardiac effects of epinephrine.

Patients with nasal conditions that could affect drug absorption should discuss this with their prescribing physician. Conditions such as severe nasal polyps, recent nasal surgery, significant nasal congestion, or active nasal bleeding could theoretically affect the absorption of intranasally administered epinephrine. In clinical studies, however, EURneffy demonstrated adequate absorption even in patients with mild upper respiratory symptoms, and the nasal route remains a viable option for most patients. If nasal congestion is a frequent concern, patients may be advised to carry an additional conventional epinephrine auto-injector as a backup.

Elderly patients and those with cardiac disease should be particularly aware that after epinephrine administration, they may experience palpitations, chest pain, or a sensation of rapid heartbeat. These effects are expected pharmacological actions of epinephrine and are generally transient. The treating emergency medical team should be informed about all pre-existing conditions so that appropriate monitoring and supportive care can be provided.

Pregnancy and Breastfeeding

Epinephrine should be used in pregnant women experiencing anaphylaxis without hesitation. Anaphylaxis during pregnancy poses a grave risk to both the mother and the fetus, including placental abruption, fetal hypoxia, and maternal death. Epinephrine remains the treatment of choice, and withholding it could have catastrophic consequences. The drug does cross the placenta and may transiently reduce uterine blood flow due to vasoconstriction, but the alternative — untreated anaphylaxis — carries far greater risks. Pregnant women who have used EURneffy should be monitored in a facility capable of fetal monitoring.

Epinephrine is present in breast milk in small quantities. Given that EURneffy is used only in emergency situations and that epinephrine has a very short half-life (approximately 2–3 minutes), breastfeeding may be continued after use. The temporary interruption of breastfeeding is not necessary following emergency epinephrine administration, though mothers may wish to discuss this with their healthcare provider.

How Does EURneffy Interact with Other Drugs?

Drug interactions with epinephrine are clinically significant in the context of anaphylaxis management because they can affect both the efficacy of treatment and the severity of adverse effects. It is essential for patients prescribed EURneffy to inform their allergist and all healthcare providers about every medication they are taking, including over-the-counter drugs, herbal supplements, and recreational substances. However, the overriding principle remains clear: no drug interaction is a reason to withhold epinephrine during an anaphylactic reaction.

Major Interactions

Non-selective beta-blockers (such as propranolol, nadolol, and timolol, including ophthalmic preparations) represent the most clinically important interaction with epinephrine. These medications block beta-adrenergic receptors, which can diminish the bronchodilatory and cardiac effects of epinephrine during anaphylaxis. Patients taking non-selective beta-blockers may experience more severe anaphylaxis, may be less responsive to standard doses of epinephrine, and may require repeated doses or additional interventions such as glucagon (which bypasses beta-receptors to increase cardiac contractility). International guidelines recommend that patients at risk of anaphylaxis should avoid non-selective beta-blockers when possible, and physicians prescribing EURneffy to patients on beta-blockers should consider whether a switch to a cardioselective beta-blocker (such as metoprolol or bisoprolol) is feasible.

Tricyclic antidepressants (TCAs) such as amitriptyline, nortriptyline, and imipramine inhibit the reuptake of norepinephrine at nerve terminals. This can potentiate the cardiovascular effects of exogenously administered epinephrine, potentially leading to exaggerated hypertension and cardiac arrhythmias. While this interaction is significant, it does not change the recommendation to use epinephrine during anaphylaxis. Rather, patients on TCAs should be monitored more closely after epinephrine use.

Monoamine oxidase (MAO) inhibitors, including phenelzine, tranylcypromine, and the reversible MAO-A inhibitor moclobemide, inhibit the enzymatic degradation of catecholamines including epinephrine. This can result in significantly enhanced and prolonged effects of administered epinephrine, with a greater risk of hypertensive crisis. As with TCAs, this interaction warrants closer monitoring but does not contraindicate epinephrine use in anaphylaxis.

Minor Interactions

Halogenated inhalational anesthetics (such as halothane, sevoflurane, and desflurane) may sensitize the myocardium to the arrhythmogenic effects of epinephrine. This is primarily relevant in the perioperative setting, where anaphylaxis may occur during general anesthesia. Anesthesiologists are well aware of this interaction and will manage epinephrine dosing accordingly.

Alpha-adrenergic blocking agents (such as phentolamine and prazosin) may reduce the vasoconstrictive effects of epinephrine, potentially diminishing its ability to counteract hypotension during anaphylaxis. Patients on alpha-blockers may require additional fluid resuscitation and vasopressor support in the emergency department.

Cardiac glycosides (such as digoxin) may increase the risk of cardiac arrhythmias when combined with epinephrine. Patients taking digoxin who receive epinephrine should have continuous cardiac monitoring.

What Is the Correct Dosage of EURneffy?

EURneffy is designed for rapid emergency use and requires no complex preparation. The device is a single-dose, single-use nasal spray that delivers the entire 2 mg dose of epinephrine in one actuation. Unlike multi-dose nasal sprays used for other conditions, EURneffy does not need to be primed before use. Each device contains exactly one dose, and once the plunger has been pressed, the device cannot be reused. Patients who carry EURneffy should always have at least two devices available, as a second dose may be necessary if symptoms persist or return.

Adults

The 2 mg nasal dose has been specifically calibrated to achieve systemic epinephrine exposure comparable to that of a 0.3 mg intramuscular injection using conventional auto-injectors. The higher nasal dose compensates for the inherent differences in bioavailability between the nasal and intramuscular routes. Pharmacokinetic bridging studies have confirmed that intranasal delivery of 2 mg epinephrine produces peak plasma concentrations (Cmax) and total exposure (AUC) within the therapeutic range required to treat anaphylaxis effectively.

Children

Clinical pharmacokinetic studies in adolescents have demonstrated that intranasal epinephrine is well absorbed in this age group. The ease of nasal administration is particularly advantageous in children and adolescents, who may resist or be frightened by needle injections. School nurses, teachers, and other caregivers can administer EURneffy more confidently than traditional auto-injectors, as no injection technique is required. Several studies have shown that lay caregivers perform intranasal administration more quickly and with fewer errors compared to auto-injector use.

Elderly

Missed Dose

The concept of a missed dose does not apply to EURneffy, as it is used only on an as-needed emergency basis and is not taken on a regular schedule. There is no maintenance dosing regimen. Patients should simply ensure they always have an unexpired device available and accessible whenever they are at risk of encountering a known or potential allergen. It is recommended to develop a habit of checking the availability and expiration date of the device regularly — for example, at the same time each month.

Overdose

An overdose of epinephrine, whether from administering multiple doses or from inadvertent use, can cause severe hypertension, tachycardia, cardiac arrhythmias (including ventricular tachycardia and fibrillation), pulmonary edema, and cerebral hemorrhage. In the event of suspected overdose, the patient should be transported immediately to an emergency department for cardiac monitoring and supportive care. The effects of epinephrine are relatively short-lived due to its rapid metabolism (half-life of approximately 2–3 minutes), and in most cases, the cardiovascular effects resolve spontaneously. However, in severe cases, treatment may include short-acting alpha-adrenergic blocking agents and beta-blockers to counteract the excessive adrenergic stimulation.

What Are the Side Effects of EURneffy?

It is important to understand that the side effects of EURneffy are largely the expected pharmacological effects of epinephrine — the very same effects that make it effective in treating anaphylaxis. Epinephrine's actions on alpha- and beta-adrenergic receptors throughout the body produce therapeutic effects (bronchodilation, vasoconstriction, cardiac stimulation) as well as effects that may be perceived as side effects (tachycardia, tremor, anxiety). In the context of an anaphylactic emergency, these cardiovascular and neurological effects are a necessary consequence of life-saving treatment and are generally well tolerated.

The safety profile of intranasal epinephrine has been evaluated in multiple clinical pharmacokinetic and pharmacodynamic studies. The overall safety profile is consistent with what is known about epinephrine administered by other routes. The intranasal delivery route adds some local nasal effects that are not seen with intramuscular injection, but these are generally mild and transient.

Side effects may feel more intense in patients who have never received epinephrine before or in those who are particularly sensitive to sympathomimetic stimulation. Patients should be counseled that experiencing a rapid heartbeat, shakiness, or anxiety after using EURneffy is expected and is not a sign that the medication is harmful. These effects typically subside within 15–30 minutes as the epinephrine is rapidly metabolized by the body.

Patients who experience any of the rare serious side effects listed above (particularly chest pain, severe palpitations, or sudden severe headache) should inform the emergency medical team immediately. These effects are more likely to occur in patients who have received multiple doses of epinephrine, in elderly patients, or in patients with pre-existing cardiovascular disease.

Local nasal side effects, including nasal discomfort, tingling, sneezing, and throat irritation, are specific to the intranasal delivery route and are generally mild. In clinical studies, these nasal effects were typically rated as mild and resolved within minutes. They are caused by the direct stimulatory effect of epinephrine on the nasal mucosa and do not indicate an allergic reaction to the medication. It is important to distinguish these expected local effects from symptoms of an ongoing anaphylactic reaction, which would involve more systemic features such as widespread urticaria, airway swelling, and hemodynamic instability.

How Should You Store EURneffy?

Proper storage of EURneffy is essential to ensure that the medication remains effective when needed in an emergency. Epinephrine is sensitive to degradation by light, heat, and oxygen. Degraded epinephrine loses potency and may not provide adequate treatment during anaphylaxis. The following storage guidelines are based on the product labeling and stability data from the manufacturer.

Temperature: EURneffy should be stored at controlled room temperature, ideally between 20–25°C (68–77°F). Brief excursions to temperatures between 15–30°C (59–86°F) are permitted, as may occur during travel or daily activities. Do not refrigerate EURneffy, as cold temperatures may affect the nasal spray mechanism and drug absorption characteristics. Do not freeze the product, as freezing may damage the device and alter the formulation.

Light protection: Keep EURneffy in its original packaging (outer carton) until ready to use. The packaging provides protection from light, which can accelerate the degradation of epinephrine. Do not store the device loose in a bag, pocket, or drawer where it will be exposed to ambient light for extended periods. If you need to carry the device for quick access, use a protective carrying case.

Visual inspection: Before use, visually inspect the solution through the viewing window of the device (if available). The solution should be clear and colorless. Do not use the device if the solution appears discolored (brownish, pinkish, or yellow), cloudy, or contains visible particles. Discoloration is a sign that epinephrine has degraded and may not be fully effective.

Expiration date: Check the expiration date printed on the device regularly. Set a reminder to replace the device before it expires. In an absolute emergency where no other epinephrine is available, using an expired device is preferable to using no epinephrine at all, as partially degraded epinephrine may still provide some benefit. However, this should be considered a last resort, and expired devices should be replaced as soon as possible.

Keep out of reach of children: While EURneffy should be accessible to authorized caregivers and the patient in an emergency, it should be stored in a location that prevents accidental use by young children. Accidental administration of epinephrine to a child can cause significant cardiovascular effects. If accidental use occurs, seek medical attention immediately.

Disposal: Used or expired EURneffy devices should be disposed of according to local regulations for pharmaceutical waste. Do not throw used devices in regular household waste if local regulations require pharmaceutical disposal. Your pharmacist can advise on proper disposal methods in your area.

What Does EURneffy Contain?

The active ingredient in EURneffy is epinephrine (also known internationally as adrenaline), at a concentration that delivers 2 mg per single actuation. Epinephrine is a catecholamine hormone naturally produced by the adrenal medulla and certain neurons in the central nervous system. The synthetic epinephrine used in EURneffy is chemically identical to the naturally occurring hormone (molecular formula: C₉H₁₃NO₃; molecular weight: 183.2 g/mol).

The inactive ingredients (excipients) in the formulation serve important functions. They maintain the chemical stability of epinephrine in solution, adjust the pH to a range that is both stable and compatible with nasal absorption, ensure proper isotonicity for nasal comfort, and include preservative agents to prevent microbial contamination. The specific excipients may include sodium chloride (for isotonicity), citric acid and sodium citrate (as pH buffer), sodium metabisulfite (as antioxidant/preservative), and purified water.

Regarding sulfites: The formulation may contain sodium metabisulfite, a sulfite that acts as an antioxidant to prevent degradation of epinephrine. Sulfites can cause allergic-type reactions in susceptible individuals, particularly those with asthma. However, the presence of sulfites should never deter the use of EURneffy during anaphylaxis. The potential risk of a sulfite sensitivity reaction is far smaller than the certain risk of untreated anaphylaxis. International guidelines explicitly state that the presence of sulfites is not a contraindication to epinephrine use in anaphylaxis.

Device description: The nasal spray device consists of a single-dose container with an actuator and nozzle designed for intranasal delivery. The device is pre-filled and pre-loaded, requiring no assembly or priming. It is designed for one-time use only. After the plunger is pressed, the entire dose is expelled, and the device cannot be reused. The device is compact enough to be carried in a pocket, purse, or bag, and is lighter and smaller than most traditional epinephrine auto-injectors.